The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance

The investigators want to investigate whether it is possible to reduce the number of curative radiotherapy doses from 5 to only 3 for men with localized early prostate cancer. The aim of the study is to ensure that the side effects of the 3-dose treatment are the same or potentially lower than those already published when using the 5-dose treatment as used in the UK PACE-B trial (NCT01584258). The name of this type of radiotherapy is Stereotactic Body Radiotherapy (SBRT) or participants may see it referred to as Stereotactic Ablative Radiotherapy (SABR). The study is a two-stage single arm Pha

Trial Details

NCT ID
NCT06117059
Phase
NA
Sponsor
NHS Lothian
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 3 fractions of prostate SBRT
Locations (sample)
  • Edinburgh, United Kingdom|55.95206,-3.19648

Key Eligibility Criteria

  • low and favorable intermediate NCCN Criteria patients
  • Prostate volume under 80cc
  • IPSS under 20
  • Q-max above 10cc per second and urinary residual less than 150mls

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →